US008821893B2

(12) **United States Patent**
Dattwyler et al.

(10) **Patent No.: US 8,821,893 B2**
(45) **Date of Patent: Sep. 2, 2014**

(54) **ORAL VACCINE FOR *BORRELIA***

(75) Inventors: **Raymond J. Dattwyler**, East Setauket, NY (US); **Maria Gomes-Solecki**, New York, NY (US)

(73) Assignee: **Bio Peptides, Corp.**, East Setauket, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 805 days.

(21) Appl. No.: **11/631,090**

(22) PCT Filed: **Jun. 30, 2005**

(86) PCT No.: **PCT/US2005/023106**

§ 371 (c)(1),
(2), (4) Date: **Aug. 3, 2009**

(87) PCT Pub. No.: **WO2006/014292**

PCT Pub. Date: **Feb. 9, 2006**

(65) **Prior Publication Data**

US 2009/0297560 A1 Dec. 3, 2009

Related U.S. Application Data

(60) Provisional application No. 60/585,057, filed on Jul. 2, 2004.

(51) **Int. Cl.**
A61K 39/02 (2006.01)
C12N 1/21 (2006.01)

(52) **U.S. Cl.**
USPC **424/235.1**; 435/252.33

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,214,008	A *	7/1980	Groben et al.	426/53
4,683,195	A	7/1987	Mullis et al.	435/6.11
4,683,202	A	7/1987	Mullis	435/91.2
4,965,188	A	10/1990	Mullis et al.	435/6.12
6,344,552	B1 *	2/2002	Flavell et al.	536/23.7
6,676,942	B1	1/2004	Lobet et al.	424/190.1

FOREIGN PATENT DOCUMENTS

EP	1084709	*	3/2001
WO	WO/01/21200		2/2001
WO	WO/02/16422		2/2002
WO	WO 02/16422	*	2/2002

OTHER PUBLICATIONS

Greenspan et al. (Nature Biotechnology 7: 936-937, 1999).*
Bowie et al (Science, 1990, 257:1306-1310).*
Fikrig et al (The Journal of Infectious Diseases, 1991:164:1224-1227).*
Hanson et al (Expert Rev. Vaccine, 2(5), 683-703, 1993).*
Willett et al (PNAS, Feb. 3, 2004, vol. 101, No. 5, p. 1303-1308).*
Abe, P. M. et al. (1978) Immunization of Mice Against *Fusobacterium necrophorum* Infection by Parenteral or Oral Administration of Vaccine, *Am. J. Vet. Res.* 39(1), 115-118.
Anderson, J. F. (1988) Mammalian and Avian Reservoirs for *Borrelia burgdorferi, Annals of the New York Academy of Sciences* 539(1), 180-191.
Anguita, J. et al. (2003) Adaptation of *Borrelia burgdorferi* in the tick and the mammalian host, *FEMS Microbiol. Rev.* 27(4), 493-504.
Balansky, R. et al. (1999) Inhibitory effects of freeze-dried milk fermented by selected *Lactobacillus bulgaricus* strains on carcinogenesis induced by 1,2-dimethylhydrazine in rats and by diethylnitrosamine in hamsters, *Cancer Letters* 147(1-2), 125-137.
Barbour, A. G. et al. (1993) The biological and social phenomenon of Lyme disease, *Science* 260(5114), 1610-1616.
Barthold, S. W. (1999) Specificity of Infection-Induced Immunity among*Borrelia burgdorferi* Sensu Lato Species, *Infection and Immunity* 67(1), 36-42.
Creekmore, T. et al. (2002) A baiting system for delivery of an oral plague vaccine to black-tailed prairie dogs, *J. Wildl. Dis.* 38(1), 32-39.
de Silva, A. M. et al. (1996) *Borrelia burgdorferi* OspA is an arthropod-specific transmission-blocking Lyme disease vaccine, *The Journal of Experimental Medicine* 183(1), 271-275.
Ding, W. et al. (2000) Structural identification of a key protective B-cell epitope in lyme disease antigen OspA, *Journal of Molecular Biology* 302(5), 1153-1164.
Dunne, M. et al. (1995) Oral vaccination with an attenuated *Salmonella typhimurium* strain expressing *Borrelia burgdorferi* OspA prevents murine Lyme borreliosis, *Infection and Immunity* 63(4), 1611-1614.
Erdile, L. F. et al. (1997) OspA lipoprotein of *Borrelia burgdorferi* is a mucosal immunogen and adjuvant, *Vaccine* 15(9), 988-995.
Estrada, R. et al. (2001) Field trial with oral vaccination of dogs against rabies in the Philippines, *BMC Infect. Dis.* 1, 23.
Fikrig, E. et al. (1990) Protection of mice against the Lyme disease agent by immunizing with recombinant OspA, *Science* 250(4980), 553-556.
Fikrig, E. et al. (1991) Protection of mice from Lyme borreliosis by oral vaccination with *Escherichia coli* expressing OspA,*Journal of Infectious Diseases* 164(6), 1224-1227.
Fikrig, E. et al. (1992) Long-term protection of mice from Lyme disease by vaccination with OspA, *Infection and Immunity* 60(3), 773-777.
Fikrig, E. et al. (1992) Elimination of *Borrelia burgdorferi* from vector ticks feeding on OspA-immunized mice, *Proceedings of the National Academy of Sciences* 89(12), 5418-5421.
Fingerle, V. et al. (1995) Expression of outer surface proteins A and C of *Borrelia burgdorferi* in *Ixodes ricinus, Journal of Clinical Microbiology* 33(7), 1867-1869.
Fletcher, W. et al. (1990) A field trial to determine the feasibility of delivering oral vaccines to wild swine, *J. Wildl. Dis.* 26(4), 502-510.

(Continued)

Primary Examiner — Padma V Baskar
(74) *Attorney, Agent, or Firm* — Medlen & Carroll, LLP

(57) **ABSTRACT**

The present invention relates to vaccines for control of *Borrelia* infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more *Borrelia burgdorferi* antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.

11 Claims, 6 Drawing Sheets